Immune Dysregulation, Not Chronic Inflammation, Characterizes PCOS Across Diverse Populations

Overview

This study analyzed cytokine profiles in premenopausal women with PCOS across racial groups and found reduced levels of multiple immune markers rather than elevated inflammatory markers. The findings challenge the prevailing concept of chronic low-grade inflammation in PCOS and suggest immune suppression and impaired angiogenic signaling as key features.

Background

Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting reproductive-age women, characterized by hyperandrogenism and ovulatory dysfunction. It is frequently associated with obesity and insulin resistance, conditions linked to chronic inflammation. Previous studies have reported inconsistent findings regarding inflammatory cytokines such as TNF-α, IL-6, and CRP in PCOS, with some showing elevation and others no difference or reduction. Ethnic and racial differences in PCOS prevalence and immune profiles further complicate understanding of its pathophysiology.

Data Highlights

Key Findings

• PCOS patients exhibited significantly lower circulating levels of multiple immune markers compared to controls, independent of race.
• Growth factors such as vascular endothelial growth factor A (VEGF-A) and platelet-derived growth factor (PDGF) were reduced in PCOS.
• Proinflammatory cytokines including IL-8, tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) were decreased in PCOS patients.
• Only IL-18 and C-X-C motif chemokine ligand 16 (CXCL16) showed significant differences between Black and White women with PCOS.
• Findings contradict the chronic low-grade inflammation hypothesis traditionally associated with PCOS, suggesting immune suppression and impaired angiogenic signaling instead.
• Results were obtained from a racially diverse, BMI-matched cohort, minimizing confounding effects of obesity.

Clinical Implications

Clinicians should reconsider the role of chronic inflammation in PCOS pathophysiology, especially in nonobese patients, and recognize immune dysregulation as a potential underlying mechanism. Targeted therapies addressing immune suppression and angiogenic dysfunction may offer new avenues for treatment. Further research incorporating larger, diverse cohorts and metabolic parameters is necessary before translating these findings into clinical practice.

Conclusion

This study challenges the prevailing view of PCOS as a chronic inflammatory disorder and highlights immune dysregulation and impaired angiogenic signaling as important factors. These insights pave the way for novel therapeutic strategies tailored to the immune profile of PCOS patients.

References

1. Gonzalez et al 1999 -- Elevated TNF-α in Normal-Weight Women with PCOS
2. Escobar-Morreale et al -- Meta-Analysis of Inflammatory Markers in PCOS
3. Aboeldalyl et al -- Systematic Review of Cytokines in PCOS